Back to Results

Extension Study of BMN 044 in Duchenne Muscular Dystrophy (DMD)

Interested in this Trial?

Contact Us

Trial Status Terminated

Trial Identifier

NCT02958202

Condition

Duchenne Muscular Dystrophy

The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.

Trial Summary

The aim of this study is to provide continuing access to BMN 044 treatment for subjects previously treated with BMN 044. The information gained from this study is expected to further characterize the efficacy and safety of BMN 044 over a longer treatment period.

Eligibility Criteria

Birth Sex

Male

Age

From 5 Years

Healthy Volunteers

No

Drug/Treatment:

BMN 044 IV 6 mg/kg, BMN 044 IV 9 mg/kg, BMN 044 SC 6 mg/kg

Phase:

Phase 2

Study Type:

Interventional

Number of Participants:

7

Study Started:

2016-04

Study Updated:

2018-01-26

Trial Locations

  • Universitair Ziekenhuis Leuven

    Leuven, , Belgium

  • S.Anna Hospital

    Ferrara, , Italy

  • Policlinico Univsersitario Agostino Gemelli

    Rome, , Italy

  • Leiden University Medical Center

    Leiden, , Netherlands

  • Drottning Silvias Barn- ochungdomssjukhus

    Goteborg, , Sweden

Inclusion Criteria

  • Subjects previously treated with BMN 044 or a comparator treatment in a BMN 044 Sponsored Study or Investigator Initiated Trial and who are not eligible for another ongoing BMN 044 study.
  • Continued use of glucocorticosteroids for a minimum of 60 days prior to study entry with a reasonable expectation that the subject will remain on glucocorticosteroids for the duration of this study.
  • Willing and able to comply with all study requirements and procedures.
  • Willing and able to provide written, signed informed consent, or in the case of subjects under the age of 18 years(or 16 years, depending on the region), provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the study has been explained, and prior to the conduct of any research-related procedures.

Exclusion Criteria

  • Subjects who have previously been treated with BMN 044 who had a serious adverse experience or met safety stopping criteria, that remains unresolved, which in the opinion of the Investigator could have been attributable to BMN 044.
  • History of significant medical disorder which may confound the interpretation of safety data
  • Acute illness within 4 weeks prior to the first dose of BMN 044 (Week 1) which may interfere with the measurements.
  • Symptomatic cardiomyopathy.
  • Baseline aPTT above the upper limit of normal (ULN).
  • Baseline platelet count below the lower limit of normal (LLN).
  • Use of anti coagulants, anti thrombotics or anti platelet agents within 28 days of the baseline visit.
  • Prior use of any investigational product (other than BMN 044) or investigational medical device must be discussed with the Medical Monitor prior to screening.
  • Current or history of drug and/or alcohol abuse

Contact BioMarin Clinical Trials

Please complete and submit the following form to express interest in participating and request more information about one of our active clinical trials

*required fields

"*" indicates required fields

Please select the trial that you are interested in from the dropdown below. Note that this list only includes currently active trials. If you cannot find the trial you are seeking, please enter the study identifier and title in the comments box below, along with any other details you would like us to know to help address your inquiry.
Consent*
Consent*
For more Information about BioMarin's privacy obligations or to exercise your privacy rights, please visit BioMarin's Data Privacy Center.
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form

What’s Next?

Visit the following links to learn more about clinical trials.

Discuss this trial with your care team.

You may wish to print this page to share the details with your healthcare providers and discuss whether you may be eligible.

Print

Get in touch.

Contact Us